Treatment-Resistant Psoriatic Arthritis Improved by Ixekizumab
Ixekizumab benefits patients with treatment-resistant psoriatic arthritis when administered over a 2- or 4-week period.
Next post in Arthritis
Ixekizumab benefits patients with treatment-resistant psoriatic arthritis when administered over a 2- or 4-week period.
